课题基金 / 基金详情

Clinical Molecular

Clinical Molecular
临床分子
批准号:
7332202
负责人:
LIONEL David LEWIS
金额:
$23.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

LIONEL David LEWIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Clinical & Molecular Pharmacology Shared Resource (CMPSR) is an extension of the Clinical Pharmacology Shared Service. Its functions are to support NCCC investigators in the design, analysis, and interpretation of clinical pharmacology objectives in preclinical studies, clinical trials, chemoprevention trials and epidemiological studies. CMPSR services include: 1) a central processing center for biological fluid (plasma/saliva/urine) and cell samples obtained as part of approved clinical and epidemiological protocols, including processing of samples (including processing peripheral blood mononuclear cells), logging and storage, aliquoting, mail-outs; 2) development of novel drug assays (when such assays are not routinely available) using HPLC (UV & fluorescence detection) and liquid chromatography/mass spectrometry methodology; 3) performance of drug concentration measurements in biological fluids and tissues for formal, approved preclinical and clinical oncology studies and trials; 4) pharmacokinetic and pharmacodynamic analysis of data from pre-clinical animal trials and clinical studies; 5) development and performance of molecular biology assays for correlative science study endpoints in tissue (usually tumor tissue) for clinical oncology studies supported by the CMPSR; 6) consultation concerning clinical study design, and pharmacokinetic and pharmacodynamic hypothesis testing in studies; 7) assistance and participation in protocol scientific review (NCCC Cancer Research Committee) and the NCCC Safety and Data Monitoring Committee) within the NCCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
  • 批准号:
    10761171
  • 项目类别:
  • 资助金额:
    $99.92万
  • 财政年份:
    2023
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
  • 批准号:
    10261525
  • 项目类别:
  • 资助金额:
    $101.56万
  • 财政年份:
    2020
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
Toxicology, Pathology and Biodistribution Core (TPB Core)
  • 批准号:
    7982610
  • 项目类别:
  • 资助金额:
    $9.59万
  • 财政年份:
    2010
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
  • 批准号:
    7944619
  • 项目类别:
  • 资助金额:
    $15.14万
  • 财政年份:
    2009
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
海外基金